Quick Answer
Acrivon Therapeutics, Inc. reported Net Income of -$77.91 million for fiscal year 2025.
Acrivon Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$77.91M +3.3% |
-$80.56M -33.4% |
-$60.39M -93.8% |
-$31.17M -91.9% |
-$16.24M | — |
| Diluted EPS | -$2.02 +15.1% |
-$2.38 +13.1% |
-$2.74 +63.8% |
-$7.56 +18.9% |
-$9.32 | — |
| Total Assets | $129.72M -34.0% |
$196.59M +42.2% |
$138.26M -23.7% |
$181.23M +70.0% |
$106.59M | — |
| Cash and Equivalents | $41.50M +4.2% |
$39.82M +10.6% |
$36.02M +22.0% |
$29.52M -70.4% |
$99.60M | — |
| Stockholders Equity | $112.52M -36.4% |
$176.79M +45.9% |
$121.19M -28.9% |
$170.47M +816.0% |
-$23.81M -183.0% |
-$8.41M |
| R&D Expense | $59.99M -6.3% |
$63.99M +39.0% |
$46.02M +92.2% |
$23.95M | — | — |
| Operating Income | -$84.11M +5.7% |
-$89.20M -32.9% |
-$67.10M -105.5% |
-$32.66M -101.8% |
-$16.18M | — |
| Shares Outstanding | 31.65M +1.3% |
31.23M +38.7% |
22.52M +2.7% |
21.92M +1138.7% |
1.77M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$18.23M | +18.7% | +13.2% |
| Diluted EPS | September 30, 2025 | -$0.47 | +20.3% | +14.5% |
| Total Assets | September 30, 2025 | $145.30M | -32.3% | -8.4% |
| Cash and Equivalents | September 30, 2025 | $35.41M | -18.4% | -15.5% |
| Stockholders Equity | September 30, 2025 | $128.60M | -34.7% | -10.1% |
| R&D Expense | September 30, 2025 | $13.65M | -27.7% | -15.7% |
| Operating Income | September 30, 2025 | -$19.69M | +21.7% | +13.1% |
| Shares Outstanding | September 30, 2025 | 31.55M | +1.3% | +0.3% |
- Acrivon Therapeutics, Inc. reported Net Income of -$77.91 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed an increase of +3.3% in Net Income compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Diluted EPS of $2.02 per share (loss) for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed an increase of +15.1% in Diluted EPS compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Total Assets of $129.72 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -34.0% in Total Assets compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Cash and Equivalents of $41.50 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed an increase of +4.2% in Cash and Equivalents compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Stockholders Equity of $112.52 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -36.4% in Stockholders Equity compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported R&D Expense of $59.99 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Operating Income of -$84.11 million for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed an increase of +5.7% in Operating Income compared to the prior fiscal year.
- Acrivon Therapeutics, Inc. reported Shares Outstanding of 31.65 million shares for fiscal year 2025.
- Acrivon Therapeutics, Inc. showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: